Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IWD vs XBI: how they differ
IWD and XBI hold 3% of their weight in the same names, and XBI returned more over the year.
iShares Russell 1000 Value ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, IWD and XBI hold 3% of their money in the same securities at the same weight.
| Holding | IWD | XBI |
|---|---|---|
| ABBVIE INC. | 1.15% | 1.04% |
| GILEAD SCIENCES, INC. | 0.44% | 0.97% |
| VERTEX PHARMACEUTICALS INCORPORATED | 0.35% | 1.06% |
| REGENERON PHARMACEUTICALS, INC. | 0.18% | 0.96% |
| AMGEN INC. | 0.16% | 1.00% |
| BIOGEN INC. | 0.09% | 1.03% |
| MODERNA, INC. | 0.07% | 1.41% |
| UNITED THERAPEUTICS CORPORATION | 0.06% | 0.93% |
| INCYTE CORPORATION | 0.05% | 1.00% |
| BIOMARIN PHARMACEUTICAL INC. | 0.03% | 0.95% |
| EXELIXIS, INC. | 0.03% | 0.96% |
| Viking Therapeutics Inc | 0.01% | 1.31% |
| Only in IWD | Only in XBI |
|---|---|
| AMAZON.COM, INC. 5.95% | Apogee Therapeutics Inc 1.49% |
| APPLE INC. 5.38% | Twist Bioscience Corp 1.41% |
| MICROSOFT CORPORATION 3.89% | Oruka Therapeutics Inc 1.38% |
| BERKSHIRE HATHAWAY INC. 2.62% | Kymera Therapeutics Inc 1.36% |
| JPMORGAN CHASE & CO. 2.46% | Praxis Precision Medicines Inc 1.29% |
| INTEL CORPORATION 1.72% | Erasca Inc 1.27% |
| JOHNSON & JOHNSON 1.72% | Revolution Medicines Inc 1.21% |
| EXXON MOBIL CORPORATION 1.60% | Rhythm Pharmaceuticals Inc 1.20% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| IWD iShares Russell 1000 Value ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | Russell 1000 value | SPDR S&P Biotech |
| Total return, 1 year | +27.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +9.9 pts | +46.5 pts |
| Expense ratio | 0.18% | 0.35% |
| Already in the S&P 500 | 90.2% | 8.5% |
| Holdings | 870 | 150 |
IWD in plain words
IWD is an index equity fund tracking the Russell 1000 value. Over the year to Sep 11, 2026 it returned +27.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.18% a year. By its holdings filed for Jun 30, 2026, 90% of the fund by weight is stocks the S&P 500 also holds, across 870 positions, with the top ten at 27.9%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IWD or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, IWD returned +27.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IWD or XBI?
- IWD charges 0.18% a year and XBI charges 0.35%, so IWD is cheaper. Fees come from each fund's prospectus.
- How much do IWD and XBI overlap with the S&P 500?
- By their latest filed holdings, 90% of IWD and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 3% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IWD against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/IWD-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources